Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1997, for OXIS International, Inc. (Note: The request metadata listed "GT Biopharma, Inc.", but the filing text explicitly identifies the registrant as OXIS International, Inc.). The company operates in the biotechnology sector, focusing on diagnostic assays, bovine superoxide dismutase (bSOD), and veterinary products. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Total Revenues | $1,162,000 | $1,367,000 |
| Net Loss | $(1,347,000) | $(1,546,000) |
| Net Loss Per Share | $(0.10) | $(0.13) |
| Cash and Cash Equivalents (End of Period) | $272,000 | $875,000 |
| Working Capital Deficit | $(2,529,000) | $(1,405,000) |
| Total Debt (Notes Payable) | $1,422,000 | $1,221,000 |
| Operating Cash Flow | $(84,000) | $(541,000) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 15% year-over-year. Product sales dropped from $1,337,000 to $1,127,000. This was driven by a $209,000 decrease in bulk bSOD sales (due to lower volume and currency fluctuations) and a $73,000 decrease in diagnostic assay sales. These declines were partially offset by a $76,000 increase in Palosein(R) sales.
- Expense Reductions: Operating expenses decreased by $370,000. Research and development (R&D) expenses fell by $76,000 due to cost reductions at the French subsidiary and the closure of the former Therox facility, though this was partially offset by increased outside development contracts. Selling, general, and administrative (SG&A) expenses decreased by $141,000, primarily due to reduced administrative costs at the French subsidiary.
- Liquidity Deterioration: The working capital deficit widened significantly from $1,405,000 to $2,529,000. Cash and cash equivalents decreased by $150,000 during the quarter. Accounts payable increased by $686,000.
- Debt Increase: Notes payable increased by $201,000 to $1,422,000, reflecting new short-term borrowings from shareholders.
Outlook, Risks, and Management Commentary
- Future Losses: Management expects to continue reporting losses in 1997 as expenses are projected to exceed revenues. There is no assurance regarding when or if revenues will exceed expenses.
- Financing Activities: In March and April 1997, the company borrowed $808,000 via short-term notes due in June/July 1997. On May 13, 1997, the company finalized an underwriting agreement to sell 9,000,000 shares of common stock on the French stock market (Le Nouveau Marche) at approximately $0.80 per share, with settlement expected by May 20, 1997.
- Operational Risks: Future sales of bulk bSOD are heavily dependent on a single Spanish licensee, with 1997 orders expected to be lower than 1996. The company's ability to realize significant revenues from new technologies depends on forming business alliances with biotechnology or pharmaceutical companies, which is not guaranteed.
- Unusual Items: Cost of sales includes approximately $180,000 in amortization of purchase adjustments from 1994 acquisitions. Excluding this, the cost of diagnostic assays was approximately 34% of sales.
Investor Verification Checklist
- Verify the closing of the French public offering (9,000,000 shares) and the receipt of proceeds by May 20, 1997.
- Confirm the repayment schedule and terms of the $808,000 in short-term shareholder notes due in June/July 1997.
- Monitor the volume of orders from the Spanish licensee for bulk bSOD, as this represents a significant revenue concentration risk.
- Assess the progress of business alliances for new product development, as current cash burn rates ($150,000 cash decrease in Q1) require external capital.
- Review the impact of currency fluctuations on bSOD sales, given the reliance on the Dutch guilder for transactions with the Spanish licensee.